Moderna announces data from Phase 1 mRNA cancer vaccine study
Category: #health  By Nikita Chaurasia  Date: 2019-06-03
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Moderna announces data from Phase 1 mRNA cancer vaccine study

The data revealed Moderna’s mRNA personalized cancer vaccine (PCV) mRNA-4157 to be well-tolerated at all tested doses and elicited neoantigen-specific T-cell responses.

Massachusetts-based biotechnology firm, Moderna, Inc. has recently announced interim data from its ongoing Phase 1 clinical study in patients with both unresected (advanced) and resected (adjuvant) solid tumors.

According to reports, the data showed Moderna’s mRNA PCV (personalized cancer vaccine) mRNA-4157, given separately or in conjunction with Merck’s pembrolizumab (KEYTRUDA®), to be well-tolerated at all tested doses and elicited neoantigen-specific T-cell responses. Furthermore, there were no vaccine-related SAEs (serious adverse events) reported for PCV when directed to patients as a monotherapy or in conjunction with pembrolizumab.

Demonstrated at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, the study showed Moderna’s mRNA platform’s immunogenicity for creating PCVs. In addition, the clinical activity was observed in some patients receiving mRNA-4157 in combination with pembrolizumab.

Reports cite that these tolerability, safety and immunogenicity data and the observed initial clinical activity support Moderna’s randomized Phase 2 study examining pembrolizumab in combination with a 1 mg dose of mRNA-4157, compared to pembrolizumab alone, for the treatment of high-risk adjuvant melanoma.

Speaking on the trial, Tal Zaks, M.D., Ph.D., CMO, Moderna, said that the company is encouraged by these interim data from its PCV program, which includes designing and manufacturing of a unique vaccine for individual patient depending on their specific tumor. Zaks claims that this study validates Moderna’s mRNA PCV’s ability to elicit T-cells that are specific to the cancer mutations.

Moreover, the company has also observed early signs of clinical activity of its personalized cancer vaccine in combination with pembrolizumab, including in two patients who were prior treated with checkpoint inhibitors.

Adding further Zaks claims that the firm is looking forward to building on these learnings about immunogenicity and tolerability by assessing activity in a randomized Phase 2 study for the treatment of adjuvant melanoma.

Source Credit: https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-presentation-interim-data-phase-1-study-mrna

https://www.biospace.com/article/releases/moderna-announces-presentation-of-interim-data-from-phase-1-study-of-mrna-personalized-cancer-vaccine-at-2019-asco-annual-meeting/

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

U.K. govt to cut BBC funding, caps viewer fees over inflation concerns

U.K. govt to cut BBC funding, caps viewer fees over inflation concerns

By Nikita Chaurasia

The British government is reportedly planning to curtail funding for the British Broadcasting Corporation (BBC), by putting a cap on the fees paid by viewers to watch the broadcasting channel for two years. According to reports, the inflation rate i...

Gmail becomes Google’s fourth app to exceed 10 billion installations

Gmail becomes Google’s fourth app to exceed 10 billion installations

By Nikita Chaurasia

The Google Play Services app, Google Maps, and YouTube are the other Google apps to achieve this milestone. Gmail was introduced back in 2004 and has since been integrated with various new features. Sources with relevant information stated that...

Quebec to levy health tax on citizens not vaccinated against COVID-19

Quebec to levy health tax on citizens not vaccinated against COVID-19

By Nikita Chaurasia

Quebec will reportedly impose a health tax on citizens who are unvaccinated against the coronavirus. The Canadian province, which has witnessed a massive number of COVID-19 related deaths in Canada, is currently battling a huge rise in the number of ...